Klin Farmakol Farm. 2011;25(2):76-78
Certolizumab and treatment of rheumatoid arthritis
- Oddělení klinické farmakologie FN Plzeň
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with frequent systemic manifestations. The introduction of
biological therapy of RA is a great progress. This treatment targets directly the pathogenesis of this disease. Certolizumab pegol is a novel
humanized monoclonal antibody that neutralizes tumor necrosis factor alfa (TNF-alfa). In contrast to other drugs it does not contain
a Fc fragment of immunoglobuline – it consists of a Fab fragment conjugated with two molecules of a polyethylene glycol. In clinical
trials, effectivity of this drug was proved both as monotherapy and in combination with methotraxate. Certolizumab brings benefit for
pacients with RA. Its structure different to other anti- TNF drugs can show to be profitable in distribution, effectivity and probably in
lower immunogenicity. Head-to-head comparison of anti TNF does not exist but some indirect comparisons reflect that certolizumab is
associated with higher risk of serious infections although the overall numbers are relatively small.
Keywords: rheumatoid arthritis, biological therapy, certolizumab
Published: June 20, 2011 Show citation
References
- Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Česká revmatologie 2010; 4(18): 182-191.
- Šenolt L. Perspektivy biologické léčby revmatoidní artritidy - nové terapeutické cíle. Farmakoterapie 2009; 6(4): 645-651.
- Vencovský J. Certolizumab pegol v léčbě revmatoidní artritidy. Remedia 2009; 19: 308-311.
- Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-811.
Go to original source... 
Go to PubMed... - Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 3319-3329. Go to original source... Go to PubMed...
- Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804. Go to original source... Go to PubMed...
- Keystone EC, Fleischmann R, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate (MTX) in the treatment of rheumatoid arthritis (RA): 2-year results from the RAPID 1 trial. Ann Rheum Dis 2009; 68(Suppl 3): 237.
- Medical Tribune, Ročník VI, Číslo 15, 14. 6. 2010.
- Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16; 2: CD008794. Go to original source... Go to PubMed...